Docoh
Loading...

PCSA Processa Pharmaceuticals

News

Pro users get this 30m faster
45 Biggest Movers From Yesterday
25 Jun 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares surged 105.3% to close at $3.51 on Thursday after the company announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.
Processa Pharmaceuticals In-Licenses Ocuphire's Anticancer Agent
17 Jun 21
Biotech, News, Penny Stocks, Health Care, Contracts, General
Processa Pharmaceuticals Says Enters Into Licensing Agreement With Ocuphire Pharma For Development Of RX-3117
17 Jun 21
News, Contracts, FDA
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ:OCUP) to license in RX-3117. RX-3117 is an oral, anticancer agent with an
12 Health Care Stocks Moving In Thursday's After-Market Session
10 Jun 21
Movers
Gainers
Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
20 May 21
News
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for
Processa Pharmaceuticals Q1 EPS $(0.14) Misses $(0.10) Estimate
13 May 21
Earnings, News
Processa Pharmaceuticals (NASDAQ:PCSA) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.10) by 40 percent.
Earnings Scheduled For May 13, 2021
13 May 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.

Press releases

Pro users get this 30m faster
Processa Pharmaceuticals to Present at "Zooming with LD Micro" Virtual Investor Event on July 29, 2021 at 12:00 p.m. ET
27 Jul 21
Press Releases
HANOVER, MD, July 27, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announced today that it will be presenting at the upcoming "Zooming with LD Micro" virtual investor event on Thursday, July
Processa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ET
6 Jul 21
Press Releases
HANOVER, MD, July 06, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announced today that the company will present at Access to Giving Virtual Conference. The presentation will be given by
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117
17 Jun 21
Press Releases
HANOVER, MD, June 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ:OCUP) to license in RX-3117.
Processa Set to Join Russell Microcap® Index
8 Jun 21
Press Releases
HANOVER, MD, June 08, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), ("Processa" or the "Company"), a clinical-stage biopharmaceutical company developing products to improve the survival and/or
Processa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET
7 Jun 21
Press Releases
HANOVER, MD, June 07, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), ("Processa" or the "Company"), a clinical-stage biopharmaceutical company developing products to improve the survival and/or
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
26 May 21
Press Releases
HANOVER, MD, May 26, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), ("Processa" or the "Company"), a clinical-stage biopharmaceutical company developing products to improve the survival and/or
Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
20 May 21
Press Releases
~Processa's trial is currently enrolling patients with ulcerated Necrobiosis Lipoidica. Detailed information on the trial can be located on clinicaltrials.gov NCT#: 04800562.~ HANOVER, MD., May 20, 2021 (GLOBE
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
18 May 21
Press Releases
HANOVER, MD., May 18, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), ("Processa" or the "Company"), a clinical-stage biopharmaceutical company developing products to improve the survival and/or
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
13 May 21
Press Releases
Clinical drug pipeline is funded and targeting major milestones in Q2 and 2H 2021 HANOVER, Md., May 13, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) ("Processa" or the
Processa Pharmaceuticals Schedules Conference Call to Discuss First Quarter Results and Provide Drug Development Update on May 13 at 5:30 p.m. EST
7 May 21
Press Releases
HANOVER, MD., May 07, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), ("Processa" or the "Company"), a clinical-stage biopharmaceutical company developing products to improve the survival and/or